Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusiness

Jubilant Life gets USFDA nod for Niacin extended release tablets

The approval granted by the US Food and Drug Administration (USFDA) to the company's wholly-owned arm Jubilant Pharma Ltd, is for multiple strengths of Niacin extended-release tablets of 500 mg, 750 mg, and 1,000 mg, the company said in a statement.

May 15, 2018 / 04:08 PM IST
Praveg Communications (India) Ltd.

Praveg Communications (India) Ltd.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Jubilant Life Sciences Ltd today said it has received the final approval from USFDA for its generic Niacin extended-release tablets used for controlling cholesterol levels.

The approval granted by the US Food and Drug Administration (USFDA) to the company's wholly-owned arm Jubilant Pharma Ltd, is for multiple strengths of Niacin extended-release tablets of 500 mg, 750 mg, and 1,000 mg, the company said in a statement.

These are the generic equivalent of AbbVie's Niaspan, which is indicated to reduce elevated high-density lipoprotein (known as bad cholesterol), among others while increasing HDL-C (good cholesterol) in patients with primary hyperlipidemia and mixed dyslipidemia.

The drug helps reduce the risk of recurrent nonfatal myocardial infarction (heart attack) in patients with a history heart disease and hyperlipidemia, the statement added.

"This is the first approval that we have received from the USFDA during the current financial year," it said.

As on March 31, 2018, Jubilant had a total of 94 ANDAs for oral solids filed in the US, the company said.

PTI
first published: May 15, 2018 04:05 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347